Aethlon Medical, Inc. (AEMD) AI Stock Analysis

Aethlon Medical, Inc. is a medical technology company based in San Diego, California, dedicated to diagnosing and treating life-threatening diseases affecting organs. The company's primary platform is the Aethlon Hemopurifier, a clinical-stage immunotherapeutic device designed to remove tumor-derived exosomes and life-threatening viruses from the circulatory system. The device has demonstrated capabilities in targeting infections such as COVID-19 and its variants. In addition, Aethlon collaborates with the University of Pittsburgh Medical Center Hillman Cancer Center to conduct studies in head and neck cancer. Founded in 1999, the company operates with 9 employees.

Aethlon Medical experienced volatile top-line results across recent periods. Revenue grew 183.2% in FY2020 to $650,187 and rose 1.4% to $659,104 in FY2021, before declining 55.4% to $294,165 in FY2022. For FY2023, revenue rose 95.2% to $574,245, contributing to a 5-year revenue CAGR of 30.9% from FY2018 to FY2023. Gross margin stood at 100.0% from FY2020 through FY2023. However, substantial operating costs and research and development expenses, which reached $2.7M in FY2023, led to an operating margin of -2072.0% and a net income of -$12.0M. For the latest quarter ended June 30, 2026, quarterly revenue growth was 4278.2% year-over-year, while trailing twelve months revenue remained at $574,245 with an EPS of -$32.97.

As of June 30, 2026, Aethlon Medical maintained $4.9M in cash and short-term investments against total debt of $367,608, resulting in net cash of $4.6M. The company reported a current ratio of 5.42 and a debt-to-equity ratio of 0.07, supported by shareholders' equity of $5.2M and total assets of $6.2M. For FY2026, capital expenditures were $3,704. To support ongoing operations and negative cash flows, such as free cash flow of -$11.4M in FY2023, the 5-year share count change reached 1903.6%.

Aethlon Medical had a market capitalization of $8.3M and an enterprise value of -$6,364 as of October 16, 2026. The stock traded at a price-to-sales ratio of 2.4x and a forward P/E of 0.2x, compared to a median price-to-sales ratio of 4.1x and forward P/E of 17.3x for its US-listed Healthcare peers. Its EV to EBITDA stood at 44.5x compared to the peer median of 12.0x. Over the 1-year period, AEMD fell 81.4%, while the SPY ETF returned 16.8%. Over 5 years, the stock returned -100.0% compared to 83.0% for the benchmark index.

Wall Street coverage on Aethlon Medical consists of 2 Hold ratings, with 0 Buy and 0 Sell ratings. The mean price target is $13.25, reflecting a 157.3% upside compared to the last close of $5.15 on October 16, 2026. For the current fiscal year ending March 31, 2027, consensus estimates project an EPS of -$5.74 and revenue of $0. In the subsequent fiscal year, 1 analyst projects an EPS of -$0.57 and revenue of $0. The company beat EPS estimates in 2 of the last 4 quarters, and its next earnings date is November 11, 2026.

This page is an AI-written research summary of Aethlon Medical, Inc. (AEMD). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: AEMD income statement, AEMD balance sheet, AEMD key metrics, AEMD analyst forecast, AEMD chart. See the AEMD stock overview for the latest quote and news.